Chromosome analysis, which was once the preferred genetic test for a wide variety of congenital abnormalities, is now one of the most frequently misordered cytogenetic tests at Mayo Medical Laboratories. This webinar will outline the differences in technologies and the appropriate use of each test.
Using targeted next-generation sequencing to identify lung tumors that may respond to targeted therapies by assessing somatic mutations simultaneously within EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2 and MET and identifying rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1.
The recommendations surrounding newborn screening are constantly in flux. Newly discovered treatments or emerging laboratory technologies are enabling additional recommendations for newborn screening.
In an effort to develop a better and more consistent flow to the Mayo Medical Laboratories Test Catalog, six new fields have been added. The “Specimen Required” section has also been reorganized.
Matt Binnicker, Ph.D., Director of the Clinical Virology Laboratory in the Division of Clinical Microbiology at Mayo Clinic, recently presented on the Clinician Outreach and Communication Activity call, “Updated CDC Zika Laboratory Testing Guidance.”